Table 2.
Characteristics of individual mCRC patients retrospectively analyzed in this study
| Age- ranges (year) | Sex | ECOG PS | Primary tumor location | Sites of metastasis when on treatment | KRAS /NRAS /BRAF mutation status | MMR or MSI status | Response and duration on prior Rego (mo) | Combining regimen | No. of cycles | Response | Regorafenib initial daily dose(mg) | Regorafenib final daily dose(mg) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 61–65 | F | 1 | Left | Liver | KRAS Mt | Unknown | PD (2) | Rego + Cam | 3 | SD | 120 | 80 |
| 2 | 61–65 | M | 0 | Right | Liver, lung | Wt | MSI-H | No Prior Rego | Rego + Sin | 16 | SD | 80 | 40 |
| 3 | 66–70 | M | 1 | Left | Lung,bone,lymph nodes, peritoneum | KRAS Mt | MSS | PD (2) | Rego + Pem | 6 | SD | 80 | 80 |
| 4 | 61–65 | M | 1 | Left | Liver, lung, lymph nodes, peritoneum | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 4 | SD | 80 | 80 |
| 5 | 71–75 | M | 1 | Right | Liver, lung | KRAS Mt | MSS | No Prior Rego | Rego + Tori | 9 | SD | 80 | 80 |
| 6 | 61–65 | F | 1 | Left | Liver, lung, lymph nodes | Unknown | Unknown | No Prior Rego | Rego + Sin | 2 | PD | 80 | 80 |
| 7 | 61–65 | F | 1 | Left | Liver, lung | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 4 | SD | 80 | 80 |
| 8 | 61–65 | F | 0 | Left | Lung | Wt | MSS | SD (1) | Rego + Cam | 1 | Unknown | 120 | 80 |
| 9 | 71–75 | M | 0 | Left | Liver | KRAS Mt | MSS | SD (6) | Rego + Sin | 13 | SD | 80 | 160 |
| 10 | 66–70 | M | 1 | Right | Lung, lymph nodes | KRAS Mt | MSS | No Prior Rego | Rego + Cam | 4 | PR | 80 | 80 |
| 11 | 61–65 | F | 2 | Right | Lymph nodes, peritoneum | Wt | Unknown | No Prior Rego | Rego + Tisle | 1 | Unknown | 80 | 80 |
| 12 | 66–70 | F | 1 | Right | Peritoneum | KRAS Mt | MSS | No Prior Rego | Rego + Nivo | 3 | SD | 40 | 80 |
| 13 | 66–70 | M | 1 | Right | Liver, lymph nodes | BRAF V600E Mt | MSS | SD (1) | Rego + Sin | 13 | SD | 80 | 160 |
| 14 | 66–70 | F | 1 | Left | Lung | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 2 | PD | 80 | 80 |
| 15 | 66–70 | F | 1 | Left | Liver, lung,bone | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 3 | SD | 80 | 80 |
| 16 | 66–70 | F | 1 | Left | Liver, lung,lymph nodes | KRAS Mt | MSS | No Prior Rego | Rego + Cam | 2 | SD | 80 | 80 |
| 17 | 76–80 | F | 1 | Left | Liver | KRAS Mt | Unknown | No Prior Rego | Rego + Tori | 6 | SD | 80 | 80 |
| 18 | 66–70 | F | 1 | Left | Liver | Unknown | MSS | SD (8) | Rego + Cam | 13 | SD | 120 | 120 |
| 19 | 66–70 | M | 2 | Right | Lung,bone,brain | KRAS Mt | MSS | No Prior Rego | Rego + Cam | 1 | Unknown | 80 | 80 |
| 20 | 71–75 | F | 2 | Left | Liver, lung,lymph nodes | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 2 | PD | 80 | 40 |
| 21 | 66–70 | F | 0 | Left | Lung, lymph nodes | KRAS Mt | MSS | SD (2) | Rego + Sin | 15 | SD | 80 | 80 |
| 22 | 66–70 | F | 1 | Left | Liver, lung,lymph nodes | Wt | MSS | No Prior Rego | Rego + Nivo | 2 | PD | 80 | 40 |
| 23 | 66–70 | M | 1 | Right | Liver | Wt | MSS | PD (6) | Rego + Sin | 6 | SD | 80 | 80 |
| 24 | 61–65 | F | 0 | Left | Lung, lymph nodes | KRAS Mt | MSS | No Prior Rego | Rego + Sin | 12 | PR | 120 | 160 |
Cam camrelizumab, ECOG PS, Eastern Cooperative Oncology Group performance status, F female, M male, mo months Mt mutant, MSI-H microsatellite instability high, MSS microsatellite stability, Nivo nivolumab, Pem pembrolizumab, PD progressive disease, Rego regorafenib, PR partial response, SD stable disease, Sin sintilimab, Tisle tislelizumab, Tori toripalimab, Wt wild-type